Introduction
adolescent psychiatrists also includes the recommendation for psychotherapy before medication in the "very young" (11) .
Both behavior therapy in the form of "parent training in behavior therapy" (also called parent behavior training) (Box), and psychostimulant medication for children are effective ADHD treatments among those aged <6 years, but the strength of evidence for behavior therapy exceeds that for psychostimulant medication (12) . Behavior therapy might require more time for achievement of full impact on child behavior and might require more resources; however, the impact lasts longer relative to ADHD medication and does not have the adverse health effects associated with these medications (12) . Approximately 30% of children aged 3-5 years who take ADHD medications experience adverse effects, most commonly appetite suppression and sleep problems, but also upper abdominal pain ("stomach ache"), emotional outbursts, irritability, lack of alertness, repetitive behaviors and thoughts, social withdrawal, and irritability when the medication wears off (12) (13) (14) . In a large efficacy trial of methylphenidate, >10% of children aged 3-5 years discontinued treatment because of adverse effects (13) . Children aged 3-5 years taking stimulant medication experience annual growth rates that are 20% lower for height (-1.4 cm/year) and 55% lower for weight (-1.3 kg/year) (12) . This finding is consistent with the rate of reduced growth among school-aged children taking stimulant medication for ADHD (15) . In school-aged children, reduced growth rates tend to attenuate over time (16) .
Based on parent-reported survey data collected just before the 2011 AAP guideline release, 53% of children with ADHD aged 4-5 years had received behavior therapy during the preceding year (the survey did not specify whether the therapy was delivered by a parent trained in behavior therapy or by a therapist or some other provider) and 47% had received medication treatment during the preceding week (17) . National rates of ADHD treatment among toddlers aged 2-3 years have not been published.
CDC compared rates of psychological services (Box) and medication treatment claims among children aged 2-5 years receiving clinical care for ADHD in the United States who were insured through Medicaid or employer-sponsored insurance (ESI). In a sample of children with ESI, comparisons were made for years preceding and following release of the 2011 AAP guidelines, to assess changes in rates of medication and psychological services for ADHD treatment among children aged 2-5 years.
Methods
CDC used two administrative claims data sources to characterize ADHD treatment patterns among children aged 2-5 years. Annual data from Medicaid Analytic eXtract files from the Centers for Medicare and Medicaid Services for 2008-2011 were used for children covered by Medicaid insurance for ≥3 continuous months during each calendar year in 29-34 states in each year, depending on data availability and usability (18) (19) (20) . During 2008-2011, the years with the most complete Medicaid data, data were available for 5-7 million children aged 2-5 years for each year from 29-34 states. Twenty-six states had data available during the entire study period. Data from Truven Health MarketScan Commercial Claims and Encounters files for 2008-2014 were used to derive estimates for children covered by ESI. Truven Health provides weights to calculate nationally-representative estimates of children covered by ESI from this convenience sample. In the analytic sample, there were approximately 1 million children aged 2-5 years in the MarketScan commercially insured population in each calendar year. The annual samples from Medicaid and MarketScan data were restricted to children with ≥3 continuous months of coverage whose covered prescription drug claims and mental health visits were included in the analytic databases.* BOX. Definitions of certain terms used in CDC analysis of Medicaid and employer-sponsored insurance claims data among children aged 2-5 years receiving clinical care for attention deficit/hyperactivity disorder (ADHD)
Psychological services for ADHD
One or more nonpharmacological treatment services included in a set of current procedure codes. These services could be provided directly to the child with ADHD or to the parent of the child with ADHD as part of the child's treatment.
Behavior therapy for ADHD
Psychological service interventions that specifically change problematic behavior, including ADHD symptoms, by altering the physical or social contexts in which the behavior occurs. Services can be delivered to the child by a therapist, teacher, parent, or other provider. (Table 2) . During 2008-2011, approximately 80% of children aged 4-5 years with ADHD received medication, compared with approximately 60% of children aged 2-3 years (p<0.001). Among children with ADHD in Medicaid, approximately 54% and 56% of children aged 4-5 years and 2-3 years, respectively, received psychological services each year; psychological service † Outpatient claims included physician, outpatient, and clinic services not related to inpatient hospital services, prescription drug services, or long-term care. § In order to include all services related to ADHD care, ADHD medication claims that did not include ICD-9 codes were included. FDA-approved medications to treat ADHD in children of any age included amphetamine and mixed amphetamine salts, atomoxetine, clonidine, dextroamphetamine, dexmethylphenidate, guanfacine, lisdexamfetamine, and methylphenidate. Only dextroamphetamine has been approved for use in children as young as age 3 years. 
Parent training in behavior therapy

Key Points
• Children diagnosed with attention deficit/hyperactivity disorder (ADHD) can be overly active, have trouble paying attention, and/or have difficulty controlling behavior. They have higher rates of grade retention, high school dropout, unintentional injuries, and emergency department visits.
• About 2 million of the more than 6 million children with ADHD were diagnosed as young children aged 2-5 years. Children with more severe ADHD are more likely to be diagnosed early.
• Behavior therapy in the form of "parent training in behavior therapy" is the recommended first-line treatment for young children with ADHD. (Figure) . The Joinpoint analyses did not detect a significant change in trend throughout the entire period (2008-2014) for either medication treatment or psychological services. During 2008-2014, the distribution of children aged 2-5 years with ESI and ADHD across treatment groups each year was just under half for medication only, approximately 15% for psychological services only, approximately 30% for both, and approximately 10% for neither treatment (Table 2) .
Each year during 2008-2014, the percentage of children aged 4-5 years with ADHD and ESI who received medication was higher (range = 77%-79%) than for children aged 2-3 years (range = 48%-58%) (p<0.001), and a higher proportion of children with ADHD aged 2-3 years received psychological services than children aged 4-5 years (46%-54% compared with 42%-45%; these differences were statistically significant in 2009, 2010, 2011, and 2014) .
Children in Medicaid and children with employersponsored insurance. For the period covered by both databases (2008-2011), correlations of state-level percentages of children in clinical care for ADHD ranged from 0.74 to 0.87 between databases. During 2008-2011, the percentage of children aged 2-5 years in Medicaid receiving clinical care for ADHD was 2.6-2.9 times greater than that of those with ESI. Across all states with available data, the percentage of children with ADHD medication claims was similar regardless of insurance status, whereas the percentage of children in Medicaid who received psychological services was 13%-22% higher than among that of those in ESI (Table 1) . Among both children in Medicaid and children with ESI, ADHD treatment rates varied substantially among states within each calendar year. Three supplemental tables and six U.S. maps showing statespecific data are available at https://stacks.cdc.gov/view/cdc/ cdc:39038 and https://stacks.cdc.gov/view/cdc/cdc:39039.
Conclusions and Comment
In 2011, the latest year for which data are available for both Medicaid and ESI populations, nearly 150,000 insured children aged 2-5 years received clinical care for ADHD, more than two-thirds of whom were Medicaid beneficiaries. Each year during 2008-2011, the percentage of children in Medicaid receiving care for ADHD was more than twice that for children with ESI. This might be accounted for by the higher percentage of children with ADHD in poverty (22), the fact that pediatric ADHD is a basis of eligibility for disability benefits, or differences in behavioral health care practices across health care systems that may result in part from state programs that seek to ensure the delivery of behavioral health services in Medicaid. In both populations, only about 50% of children with ADHD received recommended first-line therapy as measured by receipt of psychological services, whereas approximately three fourths received ADHD medication. ADHD rates varied widely across states in both insured groups, possibly because of differences in how children with ADHD are identified and served in their communities, how these services are documented, or both. There was not an increase in psychological services nor decrease in use of medication after the AAP guidelines release among children with ESI (2011-2014).
Behavior therapy for ADHD, in the form of parent behavior training, and ADHD medications are both recommended ADHD treatments (10, 12) . However, among children aged ≤5 years, the number and quality of studies demonstrating effectiveness is higher for parent behavior training than for ADHD medication (12) . In addition, young children are more susceptible to adverse health effects of ADHD medications, whereas adverse health effects have not been reported for parent behavior training (12) . ADHD treatment with behavior therapy, which is typically limited in duration, might be associated with better school outcomes (23) and more cost-effective over a school year than treatment with ongoing medication (24) . Further, behavior therapy can also improve problematic behavior in young children who present with symptoms that look like ADHD, such as symptoms of anxiety and oppositional defiant disorder. Collectively, these factors support recommendations (10,11) for parent training in behavior therapy as first-line treatment for children aged ≤5 years with ADHD.
There are barriers to the receipt of evidence-based behavior therapy training for families of young children with ADHD. First, clinical practice change following guideline or policy change takes time, and practices can vary depending on provider knowledge about the guidelines, the scale of the recommended change, and the amount of support provided to physicians (25) . Parents and physicians might lack awareness of the recommendations and benefits of behavior therapy. Families might have difficulty identifying and accessing providers of evidence-based behavior therapy, and these services might require more resources initially to access than medication. Behavior therapy might not exist in every community, and scaling up these services might be difficult and costly. To overcome these barriers, policymakers, state agencies, and health professional organizations can continue to educate parents and physicians about recommendations while expanding capacity to provide evidence-based services. State agencies and offices, such as Medicaid and Foster Care, can consider programs and policies designed to increase use of behavior therapy for ADHD, including using Title IV-E funds for the state expansion of evidence-based programs. States might also explore policies that influence prescription patterns based on existing evidence of safety and effectiveness, such as prior-authorization policies. To date, 27 state Medicaid programs have implemented prior-authorization policies for pediatric ADHD medication prescriptions.** However, it is also important to consider strategies to increase access to preferred psychological services, particularly among children who are denied medication authorization.
The findings in this report are subject to at least five limitations. First, the population evaluated was children receiving clinical care for ADHD; thus, these rates do not reflect the overall prevalence of children with ADHD. Second, the identified population did not include children in Medicaid programs for which annual data were not available, children receiving clinical care not covered by insurance, and children with a diagnosis of ADHD who had not received sufficient clinical services to meet the case definition. Third, importantly, the psychological services indicator lacked precision, and it was not possible to assess type or quality of psychological services. An inclusive list of psychological services was used as a proxy for behavior therapy with or without an ADHD ICD-code because there are no ADHD-specific behavior therapy procedure codes, although treatments for other externalizing disorders might benefit ADHD symptoms and impairment (12) , and ADHD might not have been listed as the primary or secondary diagnosis in the associated claim. Conversely, not all psychological services could be identified using these data because some might not have been covered by insurance (e.g., self-paid or delivered through the education system). However, rates of psychological services among children in this report were similar to those reported for children aged 4-5 years in 2009-2010 using national parent survey data on behavior therapy for ADHD not conditional on having insurance (17) . Fourth, results represent cross-sectional annual percentages and not lifetime diagnosis or treatment patterns. In addition, children might have been counted multiple times if their insurance status changed during the calendar year (e.g., moved to a different state Medicaid program). Finally, MarketScan data include only children with ESI and might not be generalizable to the entire U.S. population of privately insured children. However, in 2014, among the 52% of children aged 0-18 years who had private insurance, 90% were covered by ESI (26) .
ADHD is a highly prevalent condition that can lead to poor health and social outcomes (4) (5) (6) (7) (8) (9) . Despite 2007 and 2011 guidelines recommending behavior therapy as first-line treatment for children aged <6 years with ADHD, during 2008-2014 only about half of children aged 2-5 years with ADHD received psychological services. To effectively mitigate impairments associated with ADHD and minimize risks associated with ADHD medications, it is important to increase the percentage of young children with ADHD who receive evidence-based psychological services, especially parent training in behavior therapy.
